HLB PANAGENE Co., LTD. (KOSDAQ: 046210)

Market Cap	138.39B
Revenue (ttm)	29.88B
Net Income (ttm)	-5.60B
Shares Out	42.19M
EPS (ttm)	-220.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,986
Open	3,315.00
Previous Close	3,230.00
Day's Range	3,245.00 - 3,315.00
52-Week Range	2,800.00 - 5,450.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About HLB PANAGENE Co., LTD.

HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The co...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 63
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2012, HLB PANAGENE Co., LTD.'s revenue was 28.64 billion, a decrease of -30.91% compared to the previous year's 41.45 billion. Losses were -7.44 billion, 367.1% more than in 2011.